Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating and fatal disease of unknown etiology. Survival of IPF is estimated at 3 to 4 years from first medical assessment for idiopathic interstitial pneumonias (IIPs). Currently, available therapies for IPF include corticosteroid and immunosuppressant for anti-inflammatory actions unfortunately no improvements were noted for the survival of IPF. Recently, several clinical studies report on the antifibrotic outcomes for new agents of IPF. Pirfendione, Interferon (IFN)-γ, and N-acetylcysteine (NAC) are promising agents for IPF. We confirmed the efficacy of pirfenidone as a significant inhibitor for the deterioration of pulmonary functions and for decreasing the number of patients with acute exacerbations during a well designed, double blind placebo controlled randomized clinical trial in Japan. Furthermore, we adopted new methods for assessing dynamic pulmonary function by measuring minimum values of desaturation during 6 minutes walking at constant speed. Interstitial pneumonia in patients with Hermansky-Pudlak syndrome has been treated with pirfenidone in US. Pirfenidone successfully prevents worsening of %FVC for patients with %FVC>60%, but not for the group %FVC≤60%. Treatment with IFN-γ for IPF has been conducted in North America, but IFN-γ could not improve progression-free survival for the intent-to-treat group. However, IFN-γ significantly decreased the mortality ratio in patients with %FVC>60%. Recently, the evaluation of effective drugs for IPF has focused on dynamic pulmonary functions such as 6 minutes walk test, as pathological evaluation of IIPs is not recognized as a gold standard for estimating survival of patients with IPF. In this review, we introduce new strategies for the evaluation, and compounds for the treatment of IPF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have